Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose "level 0": bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1-21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study / Pozzi, Samantha; Gentile, M; Sacchi, Stefano; Marcheselli, Raffaella; Corso, A; Cocito, F; Musto, P; Guarini, A; Minoia, C; Vincelli, I; Ria, R; Rivolti, E; Mele, G; Bari, Alessia; Mazzone, C; Badiali, S; Marcheselli, Luigi; Palumbo, A; Morabito, F.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 58:3(2017), pp. 552-559. [10.1080/10428194.2016.1205741]

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

POZZI, Samantha;SACCHI, Stefano;MARCHESELLI, Raffaella;BARI, Alessia;MARCHESELLI, Luigi;
2017

Abstract

Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose "level 0": bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1-21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.
21-lug-2016
58
3
552
559
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study / Pozzi, Samantha; Gentile, M; Sacchi, Stefano; Marcheselli, Raffaella; Corso, A; Cocito, F; Musto, P; Guarini, A; Minoia, C; Vincelli, I; Ria, R; Rivolti, E; Mele, G; Bari, Alessia; Mazzone, C; Badiali, S; Marcheselli, Luigi; Palumbo, A; Morabito, F.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 58:3(2017), pp. 552-559. [10.1080/10428194.2016.1205741]
Pozzi, Samantha; Gentile, M; Sacchi, Stefano; Marcheselli, Raffaella; Corso, A; Cocito, F; Musto, P; Guarini, A; Minoia, C; Vincelli, I; Ria, R; Rivolti, E; Mele, G; Bari, Alessia; Mazzone, C; Badiali, S; Marcheselli, Luigi; Palumbo, A; Morabito, F.
File in questo prodotto:
File Dimensione Formato  
pozzi2016.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 973.08 kB
Formato Adobe PDF
973.08 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1133512
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact